Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: bkcraun who wrote (58712)	8/10/2000 10:01:51 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

LAS VEGAS, Aug 10, 2000 (BUSINESS WIRE) -- ELAST Technologies, Inc., (OTC-BB:ESTG) www.elast.com announced this morning that Thomas F. Krucker, ELAST President and CEO, will address the members of the Regional Investment Bankers Association (RIBA) during its Chicago Capital Conference, August 17th through 19th, at the Ritz Carlton Four Seasons Hotel. RIBA member James Lanni of First Midwest Securities is sponsoring ELAST Technologies' participation at the Chicago Capital Conference and during the three-day conference ELAST will be afforded the opportunity to make four separate presentations to RIBA's members. RIBA is a national trade association with offices in Charleston, South Carolina, and is comprised of approximately 135 NASD member broker/dealers. RIBA member firms managed or co-managed 706 offerings in the past 26 quarters and have raised approximately $6.6 billion in new capital. RIBA's capital conferences are held four times annually and allow its member firms to evaluate companies sponsored by other RIBA members. ELAST Technologies, Inc., is a research and development enterprise whose primary business is the development of the ELAST Device(TM). The U.S. allergy testing market is estimated to be a $6 billion annual market (and is estimated to be a $12 billion annual market worldwide). The ELAST Device(TM) is a patented, non-invasive diagnostic tool designed to accurately diagnose allergies, as well as food and chemical sensitivities immediately without any of the pain or expense associated with currently employed testing methods. Existing allergy testing methods include the oral challenge test as well as blood and skin prick testing. These methods require the introduction of the potential allergen to the body. In contrast, the ELAST Device(TM) is being designed to test for allergies and sensitivities non-invasively through means of simple exposure, without the introduction into the body of the potential allergen. The ELAST Device(TM) is based upon the clinical observation that the normal flow of electricity in the human body is altered when its immune system is exposed to a substance to which it is sensitive or allergic. The non-invasive nature of the ELAST Device(TM) is possible because the device measures the body's electrical response when it is exposed to an allergen. This news release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product development and consumer demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof. CONTACT: ELAST Technologies, Inc. Michael Nanry 877/ELASTEC 877/352-7832